Common Contracts
5 similar Purchase Agreement contracts by Ironwood Pharmaceuticals Inc, KAMAN Corp, Palo Alto Networks Inc
EX-10.1 3 d471193dex101.htm EX-10.1 Palo Alto Networks, Inc. Purchase Agreement July 10, 2018 Citigroup Global Markets Inc. Wells Fargo Securities, LLC As Representatives of the several Initial Purchasers listed in Schedule 1 hereto c/o Citigroup...Purchase Agreement • May 5th, 2020 • New York
Palo Alto Networks, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several initial purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as representatives (the “Representatives”), $1,500,000,000 aggregate principal amount of its 0.75% Convertible Senior Notes due 2023 (the “Underwritten Securities”) and, at the option of the Initial Purchasers, up to an additional $225,000,000 aggregate principal amount of its 0.75% Convertible Senior Notes due 2023 (the “Option Securities”), solely to cover overallotments, if and to the extent that the Initial Purchasers shall have determined to exercise the option to purchase such 0.75% Convertible Senior Notes due 2023 granted to the Initial Purchasers in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”. The Securities will be convertible into cash and shares, if any, (the “Underlying Securities”) of common stock o
EX-1.1 2 a15-13693_2ex1d1.htm EX-1.1 Executed Copy IRONWOOD PHARMACEUTICALS, INC. Purchase Agreement June 9, 2015 Credit Suisse Securities (USA) LLC As Representatives of the several Initial Purchasers listed in Schedule 1 hereto c/o J.P. Morgan...Purchase Agreement • May 5th, 2020 • New York
Palo Alto Networks, Inc.Purchase Agreement • July 13th, 2018 • Palo Alto Networks Inc • Computer peripheral equipment, nec • New York
Palo Alto Networks, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several initial purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as representatives (the “Representatives”), $1,500,000,000 aggregate principal amount of its 0.75% Convertible Senior Notes due 2023 (the “Underwritten Securities”) and, at the option of the Initial Purchasers, up to an additional $225,000,000 aggregate principal amount of its 0.75% Convertible Senior Notes due 2023 (the “Option Securities”), solely to cover overallotments, if and to the extent that the Initial Purchasers shall have determined to exercise the option to purchase such 0.75% Convertible Senior Notes due 2023 granted to the Initial Purchasers in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”. The Securities will be convertible into cash and shares, if any, (the “Underlying Securities”) of common stock o
Kaman Corporation Purchase AgreementPurchase Agreement • May 12th, 2017 • KAMAN Corp • Wholesale-machinery, equipment & supplies • New York
Kaman Corporation, a Connecticut corporation (the “Company”), proposes to issue and sell to the several initial purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as representatives (the “Representatives”), $175,000,000 aggregate principal amount of its 3.25% Convertible Senior Notes due 2024 (the “Underwritten Securities”) and, at the option of the Initial Purchasers, up to an additional $25,000,000 aggregate principal amount of its 3.25% Convertible Senior Notes due 2024 (the “Option Securities”), solely to cover over-allotments, if and to the extent that the Initial Purchasers shall have determined to exercise the over-allotment option to purchase such 3.25% Convertible Senior Notes due 2024 granted to the Initial Purchasers in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”. The Securities will be convertible into cash, shares of common stock of the Company, par value $1.00 pe
IRONWOOD PHARMACEUTICALS, INC. Purchase AgreementPurchase Agreement • June 15th, 2015 • Ironwood Pharmaceuticals Inc • Pharmaceutical preparations • New York
Ironwood Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several initial purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as representatives (the “Representatives”), $300,000,000 aggregate principal amount of its 2.25% Convertible Senior Notes due 2022 (the “Underwritten Securities”) and, at the option of the Initial Purchasers, up to an additional $45,000,000 aggregate principal amount of its 2.25% Convertible Senior Notes due 2022 (the “Option Securities”) if and to the extent that the Initial Purchasers shall have determined to exercise the option to purchase such Option Securities pursuant to the terms of Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”.
